Naltrexone and alcohol dependence. Role of subject compliance.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Archives of General Psychiatry

• Publication date

  1997-08-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1001/ARCHPSYC.1997.01830200071010PMID 9283509
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of naltrexone on alcohol consumption during chronic alcohol drinking and after a period of imposed abstinence in free-choice drinking rhesus monkeys

  2005cited by this paper
• Experience of a "slip" among alcoholics treated with naltrexone or placebo.

  1996cited by this paper
• Naltrexone in the treatment of alcoholism: a clinical review.

  1996cited by this paper
• Effect of naltrexone on alcohol "high" in alcoholics.

  1995cited by this paper
• Naltrexone in the treatment of alcoholism: predicting response to naltrexone.

  1995cited by this paper
• Naltrexone-induced alterations in human ethanol intoxication.

  1994cited by this paper
• The effects of selective blockade of delta and mu opiate receptors on ethanol consumption by C57BL/6 mice in a restricted access paradigm.

  1993cited by this paper
• Naltrexone and coping skills therapy for alcohol dependence. A controlled study.

  1992cited by this paper
• Naltrexone in the treatment of alcohol dependence.

  1992cited by this paper
• Ascertaining how much compliance is enough with outpatient antibiotic regimens.

  1992cited by this paper
• Naltrexone and the Treatment of Alcohol-Dependence: Initial Observations

  1990cited by this paper
• Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference.

  1990cited by this paper
• How often is medication taken as prescribed? A novel assessment technique.

  1989cited by this paper
• Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised

  1988cited by this paper
• Naltrexone blocks the post-shock increase of ethanol consumption.

  1986cited by this paper
• Antagonism by naltrexone of voluntary alcohol selection in the chronically drinking macaque monkey.

  1986cited by this paper
• Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations.

  1986cited by this paper
• Naltrexone induction: psychologic and pharmacologic strategies.

  1984cited by this paper
• Naltrexone: a clinical perspective.

  1984cited by this paper
• Strategies to improve compliance with narcotic antagonists.

  1984cited by this paper
• Delineation of anxiety and phobic disorders responsive to monoamine oxidase inhibitors: implications for classification.

  1984cited by this paper
• Survival Analysis

  1981cited by this paper
• Naltrexone: a short-term treatment for opiate dependence.

  1981cited by this paper
• Alteration of ethanol self-administration by naltrexone.

  1980cited by this paper
• The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory.

  1974cited by this paper
• Chi-square tests with one degree of freedom

  1963cited by this paper

• Evaluating the Effectiveness of Psychedelic-Assisted Therapy in Treating Alcohol Use Disorders: A Review

  2025cites this paper
• Comparative Effectiveness of Long Acting Injectable Versus Oral Naltrexone in Patients with Co-Occurring Posttraumatic Stress Disorder and Alcohol Use Disorder

  2025cites this paper
• The comparative efficacy of FDA-approved drugs for management of alcohol use disorder ‒ a network meta-analysis

  2025cites this paper
• Medical adjustment of alcohol use disorder (AUD) with opioids

  2024cites this paper
• Alcohol Use Disorder Treatment: Problems and Solutions.

  2024cites this paper
• Partial AUCs in Long-Acting Injectables: Rationale, Challenges, Variability, Usefulness, and Clinical Relevance

  2024cites this paper
• EFFICACY OF MEDICATIONS FOR THE TREATMENT OF ALCOHOL USE DISORDER (AUD): A SYSTEMATIC REVIEW AND META-ANALYSIS CONSIDERING BASELINE AUD SEVERITY.

  2024cites this paper
• Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis.

  2023cites this paper
• IUPHAR-review: The Integration of Classic Psychedelics into Current Substance Use Disorder Treatment Models.

  2023cites this paper
• Pharmacological Treatment of Alcohol use Disorder in Patients with Psychotic Disorders: A Systematic Review

  2022cites this paper
• The Added Value of Pharmacotherapy to Cognitive Behavior Therapy And Vice Versa in the Treatment of Alcohol Use Disorders: A Systematic Review

  2022cites this paper
• The life and times of endogenous opioid peptides: Updated understanding of synthesis, spatiotemporal dynamics, and the clinical impact in alcohol use disorder

  2022cites this paper
• Molecular Basis of Inhibitory Mechanism of Naltrexone and Its Metabolites through Structural and Energetic Analyses

  2022cites this paper
• Involvement of the Dorsal Vagal Complex in Alcohol-Related Behaviors

  2022cites this paper
• Traditional treatment strategies for alcoholism and the withdrawal symptoms

  2021cites this paper
• The Role(s) of Psychopharmacology in the Treatment of PTSD

  2021cites this paper
• Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: A meta‐regression analysis to develop an enrichment strategy

  2021cites this paper
• Morphine alkaloids: History, biology, and synthesis.

  2021cites this paper
• Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate: Results of a randomised, double-blind, placebo-controlled study.

  2021cites this paper
• Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.

  2021cites this paper
• Therapeutische Strategien bei Alkohol- und Tabakabhängigkeit

  2020cites this paper
• A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence

  2020cites this paper
• Pharmacotherapy of Substance Use Disorders: Challenges and Opportunities.

  2020cites this paper
• Therapeutic Strategies in Alcohol and Tobacco Addiction

  2020cites this paper
• Ätiologie der Abhängigkeitserkrankungen

  2020cites this paper
• Aetiology of Addiction

  2020cites this paper
• Systematic Review and Meta-Analysis of the Moderating Effect of rs1799971 in OPRM1, the Mu-opioid Receptor Gene, on Response to Naltrexone Treatment of Alcohol Use Disorder.

  2020cites this paper
• Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis

  2019cites this paper
• Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats

  2019cites this paper
• Testing Mediators of Reduced Drinking for Veterans in Alcohol Care Management.

  2018cites this paper
• Adding Psychotherapy to the Naltrexone Treatment of Alcohol Use Disorder: Meta-analytic Review

  2018cites this paper
• Therapeutic Drug Monitoring of Naltrexone and 6&bgr;-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges

  2018cites this paper
• Pharmacological treatments for opiate and alcohol addiction: A historical perspective of the last 50 years

  2018cites this paper
• Practical outpatient pharmacotherapy for alcohol use disorder

  2018cites this paper
• Effect of Naltrexone Hydrochloride on Cytochrome P450 1A2, 2C9, 2D6, and 3A4 Activity in Human Liver Microsomes

  2018cites this paper
• Compounds Including Cox Inhibitor Moiety and Enhanced Delivery of Active Drugs Using Same

  2018cites this paper
• Gabapentin for the treatment of alcohol use disorder

  2018cites this paper
• Naltrexone Itself Does Not Reduce Clinically-Relevant Craving

  2018cites this paper
• Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study

  2017cites this paper
• The clinical utility of the Medication Adherence Questionnaire (MAQ) in an alcohol pharmacotherapy trial.

  2017cites this paper
• Current Treatment Options for Co-Morbid Anxiety and Alcohol Use Disorders: A Review

  2017cites this paper
• Predischarge Injectable Versus Oral Naltrexone to Improve Postdischarge Treatment Engagement Among Hospitalized Veterans with Alcohol Use Disorder: A Randomized Pilot Proof‐of‐Concept Study

  2017cites this paper
• Critical Review of Alcohol, Alcoholism and the Withdrawal Symptoms. II. Treatment Strategies

  2017cites this paper
• A 25-Year-Old Woman With Bipolar Disorder, 1 Year Later

  2017cites this paper
• Patient adherence to multi-component continuing care discharge plans.

  2017cites this paper
• THE MONOAMINE STABILIZER (-)-OSU 6162-A POTENTIAL NOVEL TREATMENT FOR ALCOHOL USE DISORDERS

  2017cites this paper
• Abordaje terapéutico de los alcoholismos Therapeutical approach in alcoholic patients

  2016cites this paper
• Functional imaging of neural systems associated with alcohol reward and amphetamine toxicity

  2016cites this paper
• Functional imaging of neural systems associated with alcohol reward and amphetamine toxicity

  2016cites this paper
• Feasibility and success of cell-phone assisted remote observation of medication adherence (CAROMA) in clinical trials.

  2016cites this paper
• Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse.

  2016cites this paper
• The Zebrafish, a Novel Model Organism for Screening Compounds Affecting Acute and Chronic Ethanol-Induced Effects.

  2016cites this paper
• Alcohol-induced Locomotor Activity in Zebrafish is Mediated by Activation of the Dopaminergic System

  2016cites this paper
• Gr upSM Opioid Receptor Antagonists and Alcohol Dependence Treatment PART

  2016cites this paper
• Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence

  2016cites this paper
• Lipophilic nalmefene prodrugs to achieve a one-month sustained release.

  2016cites this paper
• Pharmacological treatments for alcohol dependence 1 SAFETY AND TOLERABILITY OF PHARMACOLOGICAL TREATMENT OF ALCOHOL DEPENDENCE : COMPREHENSIVE REVIEW OF EVIDENCE

  2016cites this paper
• Treatment of alcohol use disorder patients affected by liver cirrhosis and/or hepatocellular carcinoma awaiting liver transplantation.

  2016cites this paper
• Liver Disease and Hepatocellular Carcinoma in Alcoholics: The Role of Anticraving Therapy.

  2016cites this paper
• TIP 49: Incorporating Alcohol Pharmacotherapies Into Medical Practice

  2016influential citation
• National trends in alcohol pharmacotherapy: Findings from an Australian claims database.

  2016cites this paper
• Motivational interviewing group at inpatient detoxification, its influence in maintaining abstinence and treatment retention after discharge.

  2015cites this paper
• The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.

  2015cites this paper
• Randomized Controlled Trial of a Mobile Phone Intervention for Improving Adherence to Naltrexone for Alcohol Use Disorders

  2015cites this paper
• Candidates for liver transplantation with alcoholic liver disease: Psychosocial aspects.

  2015cites this paper
• Extended-Release Naltrexone and Harm Reduction Counseling for Chronically Homeless People with Alcohol Dependence

  2015cites this paper
• Changes in behavioral effects of delta opioid receptor agonists with ethanol consumption

  2015cites this paper
• In Vitro and In Vivo Evaluations of PLGA Microspheres Containing Nalmefene

  2015cites this paper
• Adoption of injectable naltrexone in U.S. substance use disorder treatment programs.

  2015cites this paper
• Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems.

  2014cites this paper
• Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.

  2014cites this paper
• Pharmacological Approaches to the Treatment of Alcohol Dependence in the Young

  2014cites this paper
• The role of the opioid system in alcohol dependence

  2014cites this paper
• Long-Term Outcomes of Prolonged Exposure and Naltrexone for Patients with Comorbid Posttraumatic Stress Disorder and Alcohol Dependence

  2014cites this paper
• Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders.

  2014cites this paper
• Predictors of Alcohol Treatment Outcome : Prognostic factors in cognitive behavioral therapy for problem drinking including Targeted Use of Naltrexone

  2014cites this paper
• Treatment of alcohol dependence: recent progress and reduction of consumption.

  2014cites this paper
• Outcome predictors for problem drinkers treated with combined cognitive behavioral therapy and naltrexone

  2014cites this paper
• Changes in hospital and out-patient events and costs following implant naltrexone treatment for problematic alcohol use

  2014cites this paper
• Naltrexone (50 mg) Plus Psychotherapy in Alcohol-Dependent Patients: A Meta-Analysis of Randomized Controlled Trials

  2013cites this paper
• Pharmacological Treatment of Alcohol Dependence

  2013cites this paper
• Microneedle-assisted percutaneous delivery of naltrexone hydrochloride in yucatan minipig: in vitro-in vivo correlation.

  2013cites this paper
• Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response.

  2013cites this paper
• Pharmacotherapy for alcohol dependence: status of current treatments.

  2013cites this paper
• A translational approach to novel medication development for protracted abstinence.

  2013cites this paper
• Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?

  2013cites this paper
• Predictors of Self-Reported Adherence to Naltrexone Medication in an Outpatient Treatment for Problem Drinking

  2013cites this paper
• The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies.

  2013cites this paper
• Development of a codrug approach for sustained drug delivery across microneedle-treated skin.

  2013cites this paper
• Improving clinical outcomes for naltrexone as a management of problem alcohol use

  2013cites this paper
• Formulation Optimization for Pore Lifetime Enhancement and Sustained Drug Delivery Across Microneedle Treated Skin

  2013cites this paper
• Placebo Group Improvement in Trials of Pharmacotherapies for Alcohol Use Disorders: A Multivariate Meta-Analysis Examining Change Over Time

  2013cites this paper
• Farmakoterapia wspomagająca w leczeniu uzależnienia od alkoholu i narkotyków

  2013cites this paper
• Next steps in addressing the prevention, screening, and treatment of substance use disorder in active duty and veteran Operation Enduring Freedom and Operation Iraqi Freedom populations.

  2012cites this paper
• A Translational Approach to Novel Medication Development for Protracted Abstinence

  2012cites this paper
• Unexpected N‐Demethylation of Oxymorphone and Oxycodone N‐Oxides Mediated by the Burgess Reagent: Direct Synthesis of Naltrexone, Naloxone, and Other Antagonists from Oxymorphone

  2012cites this paper
• Analysis of naltrexone and its metabolite 6-beta-naltrexol in serum with high-performance liquid chromatography

  2012cites this paper
• Factores de riesgo de recaída en pacientes drogodependientes tras desintoxicación hospitalaria Risk factors for relapse in drug-dependent patients after hospital detoxification

  2012cites this paper
• Investigating a Model for Fetal Alcohol Damage in Caenorhabditis elegans

  2012cites this paper
• Do manualized psychosocial interventions help reduce relapse among alcohol-dependent adults treated with naltrexone or placebo? A meta-analysis.

  2012cites this paper